Aiming to become a global oncology player, China's Zai Lab Ltd. is taking a leap into the hematological cancer fray by acquiring the rights to Regeneron Pharmaceuticals Inc.’s REGN1979 in mainland China, Hong Kong and Macau, in a deal worth $30m upfront and up to $160m in total.
Zai Lab CEO Samantha Du (courtesy Zai Lab)




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

